Esophagectomy in Multimodal Care for Gastroesophageal Junction Cancer

Gastroesophageal junction (GEJ) cancer develops where the oesophagus meets the stomach, a transition zone that makes treatment planning particularly complex. Tumours may behave like oesophageal or gastric cancers, and their location affects staging, surgical access, radiation fields and the extent of lymph-node dissection.

Esophagectomy remains an important treatment for selected patients, but it is rarely considered in isolation. Modern care combines systemic chemotherapy, chemoradiotherapy, surgery, nutritional support and close surveillance. The sequence depends on tumour type, stage, fitness, symptoms and the expertise of the treating multidisciplinary team.

These decisions are especially relevant in Australia, where patients may move between public hospitals, private specialists and high-volume metropolitan centres. Educational programs such as the congress registration information provided through the International Society for Diseases of the Esophagus help clinicians follow changing evidence in upper gastrointestinal oncology.

Defining The Tumour And Its Extent

GEJ cancers are commonly described using the Siewert classification. Type I tumours arise in the distal oesophagus, type II are centred at the junction, and type III extend upwards from the stomach. Although this classification remains useful, modern staging also considers the tumour’s epicentre, histology and patterns of spread.

Endoscopy with biopsy, contrast-enhanced CT and PET-CT are central to assessment. Endoscopic ultrasound can help evaluate local invasion and nearby nodes, while laparoscopy may be useful when an abdominal component is suspected. HER2, mismatch repair, PD-L1 and other biomarkers can influence systemic treatment, particularly in advanced disease.

Why Multimodal Treatment Matters

Locally advanced disease may contain microscopic cancer cells beyond the visible mass. Preoperative therapy aims to reduce this burden, improve the chance of a complete resection and treat distant micrometastases early. It may also reveal rapidly progressive disease before a patient undergoes major surgery.

Treatment pathways vary. Perioperative chemotherapy, often based on a fluoropyrimidine and platinum combination, is used in some junctional and gastric-pattern cancers. Chemoradiotherapy, such as a carboplatin-paclitaxel regimen with radiation, may be selected for tumours with an oesophageal pattern. The best approach is determined through multidisciplinary review rather than by anatomy alone.

The Surgical Contribution

Esophagectomy removes the primary tumour and regional lymph nodes, creating a pathway for food using the stomach or, in selected cases, colon. Depending on tumour position and surgical goals, an Ivor Lewis, McKeown or transhiatal approach may be considered. Junctional tumours that extend into the stomach can require an extended gastric resection instead.

The operation is technically demanding because it involves the chest, abdomen or both. Its value depends on achieving an R0 resection, meaning no tumour remains at the microscopic margin, while preserving safe reconstruction and adequate lymphadenectomy. Surgery should be undertaken by experienced teams with appropriate anaesthetic, intensive care and rehabilitation support.

Selecting Patients For Surgery

Fitness assessment is more detailed than a routine preoperative check. Clinicians consider cardiopulmonary reserve, renal function, frailty, weight loss, swallowing difficulty and the patient’s ability to recover from complications. A person with limited physiological reserve may need prehabilitation, nutritional optimisation or a different treatment goal.

In Australia, referral pathways can differ between a major Sydney or Melbourne upper-GI unit and a regional hospital. Telehealth has made specialist discussion easier for people in Queensland, Western Australia and rural New South Wales, although travel for surgery and postoperative review may still be necessary. Clear coordination between local clinicians and the tertiary centre is essential.

Managing The Risks Of Esophagectomy

Potential complications include anastomotic leakage, pneumonia, atrial fibrillation, chyle leak, infection and delayed gastric emptying. Long-term effects may include reflux, altered eating patterns, dumping symptoms and weight loss. These risks should be discussed before treatment, alongside the possibility that surgery may be abandoned if unexpected metastatic disease is found.

Enhanced recovery programs can improve mobilisation, respiratory care and return to oral intake. Patients benefit from preoperative dietitian input, smoking cessation, breathing exercises and realistic guidance about small, frequent meals. Australian hospitals commonly involve specialist nurses, speech pathologists and community services in the transition home.

Measuring Benefit And Treatment Response

The pathology report after neoadjuvant therapy and resection provides important prognostic information. Tumour regression, nodal status, margin clearance and vascular or neural invasion help determine recurrence risk and future treatment. A complete pathological response is encouraging, but it does not remove the need for structured follow-up.

Newer systemic options are changing postoperative care. Depending on residual disease, biomarkers and the original treatment regimen, adjuvant immunotherapy or further chemotherapy may be discussed. Evidence continues to develop, so treatment decisions should reflect current guidelines, trial data and the patient’s recovery.

The Role Of The Multidisciplinary Team

A specialist team may include an upper-GI surgeon, medical and radiation oncologists, gastroenterologist, radiologist, pathologist, dietitian, nurse coordinator and allied health professionals. The team reviews staging, treatment response and operative risk together, reducing fragmented decision-making.

Patient preferences also matter. Some people prioritise the greatest chance of durable control, while others place greater weight on avoiding major surgery or preserving current function. Shared discussions should cover expected survival, quality of life, hospital stay, rehabilitation and the practical demands of treatment.

For GEJ cancer, esophagectomy is best understood as one component of a carefully sequenced plan. The practical takeaway is to confirm tumour classification, complete modern staging, optimise nutrition and fitness, and have the case reviewed by a high-volume multidisciplinary upper-GI team before committing to surgery.